Compare Marathon Petroleum Corp (MPC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Natera Inc. Common Stock — how do they compare? Marathon Petroleum Corp trades at $485.15 (market cap $133.95B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Marathon Petroleum Corp is far larger — about 2.3× Natera Inc. Common Stock's market cap, and Marathon Petroleum Corp pays a 0.84% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 53 Days and Natera Inc. Common Stock for 0 Days on average.
| MPC | NTRA | |
|---|---|---|
Market Cap | $133.95B | $57.03B |
Volume | 1,644,329 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $484.92 | $425.64 |
52-Week Low | $162.63 | $179.42 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $160.47B | $56.18B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $484.92, up 5.69% today, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a reasonable P/E of 16.54. Recent news highlights refining margin strength and positive analyst sentiment, though it faces risks from potential diesel export policy shifts.
The outlook remains positive given tight refining markets and earnings growth projections, but investors should weigh policy risks and high debt levels. Wall Street consensus is strongly bullish with a $444.30 price target, though the current price exceeds this, suggesting near-term caution may be warranted despite long-term fundamentals.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
